Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319872 | 0.89 | NLRP3 (0.35) | NLRP3S1PR1 | |
| SCHEMBL24116487 | 0.84 | NLRP3 (0.37) | NLRP3 | |
| SCHEMBL23319819 | 0.83 | NLRP3 (0.37) | NLRP3 | |
| SCHEMBL29687458 | 0.83 | NLRP3 (0.48) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL20681566 | 0.83 | NLRP3 (0.48) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL25139065 | 0.79 | NLRP3 (0.43) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL22014848 | 0.78 | NLRP3 (0.35) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL20681231 | 0.78 | NLRP3 (0.35) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL30791038 | 0.78 | NLRP3 (0.35) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL20699031 | 0.76 | NLRP3 (0.34) | NLRP3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| CN-113613721-A | NLRP modulators | 诺华股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3817815-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NLRP1, NLRP3, NOD1 | NLRP3 2/4885S1PR1 466/4885RXRA 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.